In vitro experiments, FLG-AS1 upregulated HOXD10 expression by inhibiting miR-23a-3p, thereby suppressing the malignant functions of ESCC cells and reducing their cisplatin resistance. Here, HOXD10 is linked to esophageal squamous cell carcinoma.